

# **Correlation of Macular Thickness Changes and Microperimetric Values in Wet Age Related Macular Degeneration (AMD) Before and After Anti-VEGF Injection**

A thesis submitted for partial fulfillment of  
MD Degree in Ophthalmology

By

**Asmaa Abd Almonaem Mahmoud**

M.B; B.Ch., M.Sc., Cairo University

Under supervision of

**Prof.Dr. Ali Mohamed Taha**

*Professor of Ophthalmology*

*Faculty of Medicine*

*Cairo University*

**Prof.Dr. Omaima Khaled Eyada**

Professor of ophthalmology

Faculty of Medicine

Cairo University

**Dr. Iman Magdy Eissa**

Lecturer of Ophthalmology

Faculty of Medicine

Cairo University

**Dr. Riham Samy Hanafy Mahmoud Allam**

Lecturer of Ophthalmology

Faculty of Medicine

Cairo University

***Cairo University***

***2016***

## **Abstract**

**Purpose:** The aim of our study is to evaluate the effect of intravitreal bevacizumab on macular anatomical structure and macular function in eyes with wet age related macular degeneration (AMD)

**Methods:** 30 eyes with wet AMD underwent full ophthalmological examination, Amsler grid testing, macular OCT as well as macular microperimetry before receiving loading dose of bevacizumab and after one month of treatment. Topography and Microperimetry overlay was used. The location and stability of fixation were assessed.

**Results:** There was a statistically significant improvement of macular thickness map as well as the best corrected visual acuity (BCVA) but the improvement of macular sensitivity was not significant. There was a significant positive correlation between the baseline visual acuity (VA) of 0.05 or less and the change occurred in VA .There was no significant correlation between the improvement in macular thickness and the change in macular sensitivity. There was no significant correlation between the improvement in visual acuity and the improvement in macular sensitivity.

**Conclusion:** although early diagnosis and proper treatment are essential for the best outcome regarding both structural improvement and restoration of functional vision, there is still a chance for low vision eyes to restore a reasonable vision.

**Key words:** Age related macular degeneration (AMD), Microperimetry, optical coherence tomography (OCT), retinal sensitivity, Anti –VEGF, macular thickness.

## **Acknowledgement**

First and foremost, I thank ALLAH, the most gracious and merciful for HIS infinite gifts.

I would like to express my sincere appreciation and gratitude to **Prof.Dr. Ali Mohamed Taha**, Professor of Ophthalmology, Faculty of Medicine, Cairo University, for his great co-operation, unlimited help and continuous guidance during this work; I am deeply touched by his help and concern.

I am deeply grateful to **Prof.Dr. Omaila Khaled Eyada, Professor of ophthalmology, Faculty of Medicine, Cairo University**, for her great effort and supervision through out this work.

No words can describe the enormous efforts of **Dr. Iman Magdy Eissa, Lecturer of Ophthalmology, Faculty of Medicine, Cairo University**, for her honest assistance which made the achievement of this work possible.

I am deeply grateful to **Dr. Riham Samy Hanafy Mahmoud Allam, Lecturer of Ophthalmology, Faculty of medicine, Cairo University**, for her continuous supervision and help which made the achievement of this work possible.

## **Table of contents**

Acknowledgement

Table of contents ..... I

List of abbreviations ..... II

List of figures ..... IV

List of tables ..... VII

Review of literature

Age related macular degeneration ..... 1

Diagnosis of AMD and role of investigations ..... 5

Microperimetry and AMD ..... 12

Treatment of AMD and role of Anti-VEGF ..... 19

Patients and methods ..... 25

Results ..... 33

Discussion ..... 72

Conclusion ..... 82

Summary ..... 83

References ..... 85

Arabic summary

## **List of abbreviations**

ARM	Age related maculopathy
AMD	Age-related Macular Degeneration
BCVA	best corrected visual acuity
BCEA	bicurve ellipse area
CFT	central foveal thickness
CNV	choroidal neovascularization
dB	decibel
BF	Factor B
FDA	Food and drug administration
FRLs	functional retinal loci
IOP	Intraocular pressure
MP	microperimetry
NSAIDs	Non steroidal anti inflammatory drugs
OCT	optical coherence tomography
PDT	photodynamic therapy
PED	Pigment epithelial detachment
PRLs	preferred retinal loci
RPE	retinal pigment epithelium

SNPs	single nucleotide polymorphism
SD-OCT	Spectral domain-optical coherence tomography
VEGF	vascular endothelial growth factor
VA	visual acuity

## **List of figures**

Fig. (1): Neovascular AMD.	2
Fig. (2): Algorithm showing clinical classification of AMD	5
Fig. (3):Cross-sectional optical coherence tomography (OCT) images showing the three different types of choroidal neovascularization (CNV).	7
Fig. (4):Cross-sectional optical coherence tomography (OCT) images showing different types of choroidal neovascularization (CNV).	9
Fig. (5): Occult choroidal neovascularization membrane.	10
Fig. (6):Cross-sectional Cirrus HD-OCT (Carl Zeiss Meditec, Inc., Dublin, CA) image of a fibrovascular pigment epithelium detachment (PED) before and after retinal pigment epithelium (RPE) rip.	11
Fig. (7): microperimetry exam Screen Display	15
Fig. (8): Spectral OCT/SLO - Optical Head Side View	15
Fig. (9): OCT/SLO System Label.	16
Fig. (10): Left, Segmented spectral-domain optical coherence tomography (SD-OCT) image from an eye with early age-related macular degeneration. (Right) MP-1 microperimetry10-2 visual field superimposed on a color funds photo.	17
Fig. (11): Algorithm showing treatment guidelines for exudative AMD	23
Fig. (12): Algorithm showing treatment guidelines for exudative AMD	24
Fig. (13): Amsler grid chart no.1.	27
Fig.(14): An example of maular topography –microperimetry overlay obtained by OPKO Spectral OCT/SLO combination imaging system; OPKO Instrumentation, LLC, USA ,soft ware version 1.89 .	29
Figure (15): Gender distribution of the study group.	33
Fig. (16): Bar chart showing the statistical values of refractive error.	35
Fig. (17): line graph showing the statistical values of the average of IOP across follow up visits.	36
Fig. (18): Bar chart showing statistical values of biomicroscopic fundus examination findings.	38

Fig. (19): Bar chart showing statistical values of unchanged findings on biomicroscopic fundus examination.	38
Fig (20): Bar chart showing statistical values of the abnormal findings on Amsler grid testing.	40
Fig. (21): An illustrative diagram showing summarization of the 25 points of point thickness map into 5 points.	42
Fig. (22): Whiskers' box plots showing percentage of change in CFT (A) and percentage of change in average macular thickness (B).	44
Fig. (23) : Whiskers' box plots showing percentage of change in mean thickness of all points(A) ,central point(B), upper temporal quadrant (C), upper nasal quadrant (D), lower temporal quadrant (E), lower nasal quadrant (F).	45
Fig. (24): Bar chart showing statistical values of IS/OS integrity.	46
Fig. (25): Bar chart showing statistical values of RPE integrity.	47
Fig. (26): Bar chart showing statistical values of other OCT findings.	48
Fig. (27): Bar chart showing statistical values of the presence of sub retinal fluid.	49
Fig. (28): Bar chart showing statistical values of intraretinal fluid.	50
Fig. (29): An illustrative diagram showing summarization of the 25 points of point sensitivity map into 5 points.	52
Fig. (30) : Whiskers' box plots showing percentage of change in mean sensitivity of all points(A) ,central point(B), upper temporal quadrant (C), upper nasal quadrant (D), lower temporal quadrant (E), lower nasal quadrant (F)	54
Fig. (31): Bar chart showing statistical values of location of fixation	55
Fig. (32): Bar chart showing statistical values of stability of fixation.	56
Fig. (33): Line graph showing a weak negative linear correlation between percentage of change in mean point thickness and percentage of change in mean point sensitivity.	58
Fig. (34): Line graph showing a weak negative linear correlation between percentage of change in point thickness and percentage of change in point sensitivity of upper nasal quadrant.	58
Fig. (35): Line graph showing weak positive linear correlation between percentage of change in point thickness and percentage of change in point sensitivity of upper temporal quadrant.	59
Fig. (36): Line graph showing moderate negative linear correlation between percentage of change in point thickness and percentage of change in point	59

sensitivity of lower nasal quadrant.	
Fig. (37): Line graph showing moderate negative linear correlation between percentage of change in point thickness and percentage of change in point sensitivity of lower temporal quadrant.	60
Fig. (38): Line graph showing weak positive linear correlation between percentage of change in point thickness and percentage of change in point sensitivity of the central point.	60
Fig. (39): Line graph showing weak negative linear correlation between baseline visual acuity and percentage of change in mean point sensitivity.	61
Fig. (40): Line graph showing weak negative linear correlation between percentage of change in visual acuity and the percentage of change in mean point sensitivity.	62
Fig. (41): Whiskers' box blot showing Spearman rank correlation between base line Is/Os junction continuity and the percentage of change in mean sensitivity of all points.	63
Fig. (42): A composite figure of 69 year old male patient before and after treatment with deterioration of retinal sensitivity in spite of resolving of intra retinal and sub retinal fluid.	65
Fig. (43): A composite figure of 73 year old female patient before and after treatment with improvement of retinal sensitivity after resolving of intra retinal fluid.	66
Fig. (44): A composite figure of 73 year old female patient before and after treatment with some improvement of retinal sensitivity.	67
Fig. (45): A composite figure of 76 year old male patient before and after treatment with no improvement of VA or retinal sensitivity in spite of resolving of intra retinal and sub retinal fluid.	68
Fig. (46): A composite figure of 60 year old female patient before and after treatment with worsening of retinal sensitivity in spite of resolving of intra retinal cystic spaces.	69
Fig. (47): A composite figure of 67 year old female patient before and after treatment with same VA. Although retinal sensitivity became worse fixation of the eye remained central but relatively unstable.	70
Fig. (48): A composite figure of 55 year old female patient before and after treatment with fixation of the eye remained predominantly central and stable with some improvement of retinal sensitivity after resolving of intra retinal fluid.	71

## **List of tables**

Table (1): Anti-VEGF types	20,21,22
Table (2): Statistical values of VA	34
Table (3): statistical values of IOP at baseline and follow up.	36
Table (4): Statistical values of biomicroscopic fundus examination.	37
Table (5): Statistical values of the abnormal findings on Amsler grid testing.	40
Table (6): statistical values of thickness map.	43
Table (7): Percentage of change in point thickness map.	44
Table (8): statistical values of IS/OS junction.	46
Table (9): Statistical values of fragmented RPE.	47
Table (10): Statistical values of sub retinal fluid.	48
Table (11): Statistical values of intraretinal fluid.	49
Table (12): Statistical values of test duration.	51
Table (13): Statistical values of point sensitivity.	53
Table (14): Percentage of change in point sensitivity.	53
Table (15): Statistical values of location of fixation	55
Table (16): Statistical values of stability of fixation	56
Table (17): Correlations between percentages of change in point thickness and percentages of change in point sensitivity.	57
Table (18): comparison between the RPE layer integrity at baseline and the percentage of change in mean sensitivity of all points.	64

## **Aim of the work**

The aim of this study is to demonstrate the effect of the Anti-VEGF bevacizumab on macular functions represented as macular sensitivity measured by microperimetry as well as macular anatomical structure assessed by Optical Coherence Tomography (OCT) in wet age related macular degeneration (AMD).

## **Age Related Macular Degeneration**

### **Definition**

Age-related Macular Degeneration (AMD) is a progressive, degenerative disease of the macula, which is responsible for sharp vision. When the macula is damaged, the ability to see fine details and colors is threatened. If not treated, the damage may be permanent, and the visual loss may be irreversible; in other words, the untreated patient may become legally blind (According to the American Foundation for the blind legal blindness is a visual acuity of 20/200 or less, according to Snellen Eye Chart, in the better-seeing eye with best conventional correction or a visual field of 20 degrees in the better-seeing eye). (Nguyen et al., 2013)

### **Incidence and Prevalence**


AMD is the leading cause of irreversible loss of visual acuity in patients over the age of 50 in the United States. About 1.75 million United States residents had advanced AMD with associated visual loss at 2004, and that number is expected to grow to almost 3 million by 2020. (Friedman et al., 2004)

### **Risk factors**

While aging is the major risk factor for AMD, other systemic risk factors such as tobacco smoking, obesity, and sunlight exposure have also been found to be common in the development of AMD. In addition, studies of the genetic basis of AMD have revealed variations in landmark genes such as *HTRA1* and *CFH* that account for as much as 50% of the genetic risk of AMD (Zhang et al., 2012).

## **Disease progression**

There are two forms of AMD: dry and wet (neovascular). While dry AMD is most common, wet AMD is associated with more sudden and severe visual loss. Approximately 10-15% of dry AMD cases progress to wet AMD. Wet AMD is known clinically as choroidal neovascularization (CNV). ( Wang et al., 2010)



**Fig. (1):** Neovascular AMD. A healthy eye without AMD (Panels A, B) has a normal retina without signs of bleeding on color fundus photograph (A). On optical coherence tomography (OCT) image, the anatomical structure of a healthy retina is intact (B). In neovascular AMD, bleeding under the retina due to choroidal neovascularization (blue arrows) disrupts the retinal anatomy (D) and can lead to hemorrhage under the macula (C) that can cause dramatic sudden loss of sharp vision. (Nguyen et al., 2013)

## **Pathogenesis:**

An important association of the complement cascade with AMD has recently been made but we still do not understand the pathogenesis of

the disease which is characterized by loss of the retinal pigment epithelium (RPE) within the macula and in turn loss of the overlying foveal photoreceptors. ( **Wang et al., 2010**) therefore there are many theories that tried to explain how this happens. Of these, the fibrotic theory, the inflammatory and the genetic are the most commonly discussed.

### **Fibrotic Theory**

Wang 2010 believes that the onset of dry AMD is started by aging changes in Bruch's membrane and subsequent death of many RPE cells in the macula and overlying photoreceptor cells. Progression of dry AMD to wet AMD is marked by the development of neovascularization within Bruch's membrane and sub retinal space. This neovascular formation is linked to a fibrotic response leading to scar tissue and further damage to Bruch's membrane, and the photoreceptor cells. ( **Wang et al., 2010**)

### **Inflammatory Theory**

In 1994 histopathological studies have shown inflammatory cells, including macrophages and lymphocytes, in AMD lesions (**Dastgheib and Green, 1994**). By 2002 drusen have been shown to contain C3 and C3a fragments of complement, and complement deposition has been identified in the Bruch's membrane of AMD patients (**Anderson et al., 2002**). However, it remains unclear whether such inflammatory reactions are causative or secondary to the disease. Later on several studies suggest that the complement cascade is involved in the pathogenesis of AMD, and that polymorphisms in complement H are genetically linked to AMD (**Edwards et al., 2005**). Recently, intraocular expression of CCR3,

which is a chemokine, was implicated in the development of CNV (**Takeda et al., 2009**).

However, the population-based cohort Blue Mountain Eye study, found no association between the use of systemic anti-inflammatory drugs (NSAIDs or corticosteroids) and either the cross-sectional prevalence or the longitudinal incidence of AMD ( **Wang et al., 2003**). Nevertheless, there is significant evidence linking AMD to inflammatory pathways. ( **Wang et al., 2010**)

## **Genetic Theory**

**Meyers et al., 1995** suggested Genetic contributions in at least 25% of AMD patients. Indeed, single nucleotide polymorphism (SNPs) in the gene encoding complement Factor H (CFH) have been linked to susceptibility to AMD, and allelic variants in two other complement related genes, Factor B (BF) and complement component C2, have also been linked to AMD (**Gold et al., 2006**). Other candidate genes have also been reported to link to AMD, including ELOVL4, VLDLR, and LRP6 (**Haines et al., 2006**).